Xeloda

Phase 3Small molecule

Roche

Xeloda is one of 158 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

157

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Breast CancerActive, not recruiting

Colorectal CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Gastric CancerActive, not recruiting

Nasopharyngeal CarcinomaPhase 3

Active, not recruiting

Metastatic Colorectal CancerPhase 3

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Colorectal CancerPhase 3

Active, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

Gastric CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Xeloda

Roche

Phase 3

8 2

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 3

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 4

MS Contin

Merck & Co.

Preclinical

2 5

Blenoxane

Bristol-Myers Squibb

Preclinical

1 6

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 8

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 9

Chirocaine

PPurdue Pharma LP

Preclinical

1 10

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Breast Cancer

NCT06409390

Q3 2029

Post-ApprovalRecruiting

Study completion

NCT07158164

Clinical

Trials by Indication[1]

Breast Cancer8 trials

Efficacy and Safety Of Xeloda as Sequential Adjuvant Therapy After Chemotherapy in Breast Cancer

Unknown status·TTianjin Medical University·Phase 2/3·NCT01662128·600 enrolled

A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN)

Completed·GGBG Forschungs GmbH·Phase 3·NCT00196872·3,000 enrolled

A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer.

Terminated· Roche logo

Roche·Phase 2·NCT00576901·23 enrolled

Show 5 more trials

Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast Cancer

Unknown status·XXinjiang Medical University·Phase 2·NCT02489409·120 enrolled

A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer

Terminated· Roche logo

Roche·Phase 4·NCT00087620

A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer

Completed· Roche logo

Roche·Phase 2·NCT02748213·225 enrolled

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT06409390·15 enrolled

Abraxane Combined With Xeloda as Neo-Adjuvant Chemotherapy in Early Breast Cancer

Unknown status·ZZhejiang Cancer Hospital·N/A·NCT03647514·50 enrolled

Pancreatic Cancer3 trials

Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT01459614·44 enrolled

Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT02324543·47 enrolled

QYHJ Granules Versus Xeloda in Metastatic Pancreatic Cancer

Unknown status·FFudan University·Phase 2·NCT01796782·60 enrolled

Metastatic Colorectal Cancer3 trials

Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT01679327·100 enrolled

Xeloda Maintenance Versus BSC in Metastatic Colorectal Cancer

Terminated·SSamsung Medical Center·Phase 3·NCT02060669·10 enrolled

Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer

Completed·CCentre Oscar Lambret·Phase 3·NCT00905047·89 enrolled

Capecitabine3 trials

A Bioequivalence Study of Capecitabine Tablets

Completed· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT01846650·36 enrolled

A Bioequivalence Study of Capecitabine Tablets 500 mg in Adult Cancer Patients Under Fed Condition

Unknown status· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 1·NCT03435666·45 enrolled

Capecitabine Pharmacokinetics(PK)-Actual Versus Ideal Body Weight

Completed·UUniversity of Wisconsin, Madison·N/A·NCT01828554·8 enrolled

Gastric Cancer2 trials

Trial Comparing Capecitabine Plus Oxaliplatin (XELOX) and Capecitabine (X) as First-line Chemotherapy in Elderly Patients With Advanced Gastric Cancer

Withdrawn·SSamsung Medical Center·Phase 3·NCT01470742

Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer

Terminated·NNational Cancer Centre, Singapore·Phase 1·NCT02720926·3 enrolled

10 more indications

Nasopharyngeal Carcinoma2 trials

Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma

Unknown status·SSun Yat-sen University·Phase 3·NCT02786641·235 enrolled

Effect of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy in High Risk Nasopharyngeal Carcinoma

Unknown status·SSun Yat-sen University·Phase 3·NCT02621970·534 enrolled

Colorectal Cancer1 trial

SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients

Unknown status·PPeking University Cancer Hospital & Institute·Phase 3·NCT03448549·1,191 enrolled

Solid Tumours1 trial

Safety of Xeloda in Solid Tumours

Completed· Roche logo

Roche··NCT02479217·1,268 enrolled

Gastrointestinal1 trial

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

Completed· Roche logo

Roche·Phase 2·NCT00448136·83 enrolled

Metastatic Tumors1 trial

Phase II Study for Solid Metastatic Tumors

Completed·NNYU Langone Health·Phase 2·NCT02474186·41 enrolled

Metastatic Cancer1 trial

OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.

Completed· Roche logo

Roche·Phase 4·NCT00577031·205 enrolled

Head and Neck Squamous Cell Cancer1 trial

Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer

Terminated·MMultiVir, Inc.·Phase 1/2·NCT02842125·4 enrolled

Bone Metastases1 trial

Concurrent Xeloda and Radiotherapy for Bone Metastases

Unknown status·RRambam Health Care Campus·Phase 2·NCT00192777·20 enrolled

Radiation Therapy1 trial

Preoporative Bevacizumab, Radiation Therapy, and XELOX Chemotherapy for Locally Advanced Nonmetastatic Rectal Cancer

Unknown status·SSun Yat-sen University·Phase 2·NCT01818973·45 enrolled

Unspecified1 trial

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment

Recruiting·RRutgers, The State University of New Jersey·Phase 4·NCT07158164·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 30 trial records for Xeloda. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Xeloda compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Xeloda. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

Xeloda

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2029

Trials by Indication[1]

Breast Cancer8 trials

Pancreatic Cancer3 trials

Metastatic Colorectal Cancer3 trials

Capecitabine3 trials

Gastric Cancer2 trials

Nasopharyngeal Carcinoma2 trials

Colorectal Cancer1 trial

Solid Tumours1 trial

Gastrointestinal1 trial

Metastatic Tumors1 trial

Metastatic Cancer1 trial

Head and Neck Squamous Cell Cancer1 trial

Bone Metastases1 trial

Radiation Therapy1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News